Enhancing Patient Safety: Exploring Clinical Implications for the New CDC/NHSN Metric - Hospital Onset Bacteremia

This webinar was recorded live on March 20, 2024.
It is available on demand through March 31, 2026. Register above for access
Please note that this webinar is not accredited.

Description

Hospital Onset Bacteremia & Fungemia (HOB) is a new metric proposed by the CDC for National Healthcare Safety Network (NHSN) volunteer reporting this calendar year. Join Drs. Kalvin Yu and Samantha Bastow as they delve into their recent research papers, elucidating the disparities between HOB and Central Line-associated Bloodstream Infection (CLABSI). They will explore the impact of urine sources on Catheter Associated Urinary Tract Infections (CAUTI) and non-catheter Hospital Onset UTIs contributing to HOB. Additionally, discover the clinical and health economic significance of specimen collection and diagnostic stewardship.

The presentation will be followed by a live Q&A with the speakers.

Target audience

This activity is designed for physicians, lab supervisors, lab directors (and/or assistant directors), lab managers (supervisory and/or non-supervisory), medical technologists, pathologists, fellows, residents, and other laboratory professionals overseeing/conducting within this topic.

Learning objectives

At the end of this session, participants will be able to:

• Describe the difference between CLABSI and HOB.
• Outline the patient safety risks and healthcare system economic implications of HOB.
• Describe how CAUTIs and non-catheter UTIs play a role in HOB events, and what clinicians can do to help mitigate related clinical issues as detailed in 3 specific peer reviewed papers.

Faculty

Kalvin Yu, MD, FIDSA
Vice President, Medical Affairs, North America
Becton, Dickinson and Company
Franklin Lakes, NJ, USA

Samantha Bastow, PharmD, MBA
Associate Director, Medical Affairs
Becton, Dickinson and Company
Franklin Lakes, NJ, USA

Disclosures and statement of independence

The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.

The following faculty reported financial relationships:

• Kalvin Yu, MD, FIDSA
  • Stocks/Bonds: BD
  • Salary: BD

• Samantha Bastow, PharmD, MBA
  • Stocks/Bonds: BD
  • Salary: BD

Content validity

All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; AND/OR all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.